DelveInsight’s report, “Netherton Syndrome Market Insight, Epidemiology, and Market Forecast–2036,” provides a comprehensive analysis of the Netherton Syndrome landscape. The report delivers detailed insights into the disease, including historical and forecasted epidemiology, helping stakeholders understand diagnosed prevalence, patient burden, and market opportunities across key regions.

Additionally, it examines Netherton Syndrome market dynamics, offering a thorough assessment of current treatment practices, unmet needs, and emerging therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and commercialization initiatives.

To know in detail about the Netherton Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/netherton-syndrome-market

Key Takeaways from the Netherton Syndrome Market Report

• The Netherton Syndrome market size in the 7MM is projected to increase significantly by 2036, mainly due to the launch of upcoming therapies and improved diagnosis rates.

• The United States accounted for the highest market size among the 7MM in 2025.

• In 2025, the total diagnosed prevalent cases of Netherton Syndrome across the 7MM were approximately 4,000.

• The US accounted for nearly 2,000 diagnosed prevalent cases in 2025.

• EU4 and the UK represented around 47% of the total diagnosed prevalent cases in 2025, while Japan accounted for nearly 4%.

• Leading companies advancing the pipeline include Quoin Pharmaceuticals, BioCryst Pharmaceuticals, and Azitra, with promising candidates such as QRX003, BCX17725, and ATR-12.

• QRX003 is in Phase II/III development, with topline data anticipated in the second half of 2026, positioning it as one of the most advanced emerging therapies.

• BCX17725 received US FDA Fast Track designation, reflecting strong regulatory support for accelerated development.

• ATR-12 has shown encouraging early clinical progress and could emerge as a potentially transformative therapy targeting the root cause of the disease.

Key Factors Driving the Netherton Syndrome Market

• Rising Awareness and Earlier Diagnosis Rates: Increasing awareness of rare genetic skin disorders, along with broader access to advanced molecular diagnostics, is enabling earlier and more accurate diagnosis. Improved recognition among healthcare professionals and patients is expected to expand the identified treatment-eligible population.

• High Unmet Need Driving Innovative Therapies: The absence of approved disease-specific therapies continues to create substantial unmet need in the market. Current management primarily focuses on symptomatic relief, creating strong opportunities for novel targeted treatments that address the underlying disease pathology.

• Regulatory Incentives Accelerating Pipeline Development: Supportive regulatory pathways such as Orphan Drug Designation and Rare Pediatric Disease Designation are encouraging research and development activities. These incentives are helping accelerate clinical advancement, streamline approvals, and attract investment into rare disease pipelines.

• Severe Disease Burden Supporting Premium Pricing Potential: The lifelong and severe nature of the disease, combined with high per-patient healthcare costs and long-term management needs, supports premium pricing opportunities for effective novel therapies. Innovative treatments offering meaningful clinical benefit are expected to gain strong market value.

Netherton Syndrome Market Analysis

• There is currently no approved therapy specifically for Netherton Syndrome. Existing management focuses on symptomatic relief through emollients, moisturizers, keratolytics, topical corticosteroids, calcineurin inhibitors, antihistamines, antibiotics, and off-label systemic therapies. These options help manage symptoms but do not target the underlying genetic cause.

• Topical corticosteroids and calcineurin inhibitors such as tacrolimus and pimecrolimus are widely used to control inflammation and itching; however, increased skin permeability may elevate the risk of systemic absorption and safety concerns.

• Severe or refractory cases may require systemic interventions including retinoids, intravenous immunoglobulin (IVIG), immunosuppressants, and selected off-label biologics, though durable long-term efficacy remains limited.

• The market represents a significant unmet need due to the absence of disease-modifying therapies that address SPINK5 mutations, LEKTI deficiency, immune dysregulation, and chronic barrier impairment.

Get a Free sample for the Netherton Syndrome Market Forecast, Size & Share Analysis Report: Netherton Syndrome Market Forecast

Netherton Syndrome Competitive Landscape

Key companies such as Quoin Pharmaceuticals, BioCryst Pharmaceuticals, and Azitra are leading the pipeline with differentiated approaches that could transform future treatment options and create meaningful commercial opportunities.

QRX003 (Quoin Pharmaceuticals): Phase II/III topical lotion developed using proprietary delivery technology containing a broad-spectrum serine protease inhibitor designed to replicate missing LEKTI function, normalize excessive skin shedding, and strengthen the impaired skin barrier. Topline data is expected in the second half of 2026. The therapy has received US FDA Orphan Drug Designation and Rare Pediatric Disease Designation.

BCX17725 (BioCryst Pharmaceuticals): Novel KLK5 inhibitor designed to suppress abnormally active skin protease pathways in Netherton Syndrome and address the underlying protein deficiency, potentially offering disease-modifying benefit beyond symptomatic control. The therapy received US FDA Fast Track Designation, with initial Phase I patient data expected by the end of Q1 2026 and a pivotal study planned in 2027.

ATR-12 (Azitra): Live biotherapeutic topical candidate based on a genetically modified strain of S. epidermidis engineered to deliver rhLEKTI-D6 and restore LEKTI function directly at the skin barrier. Its auxotrophic design is intended to enhance safety and it may emerge as a potentially curative therapy. Phase Ib topline data is expected in Q1 2026, supported by encouraging early safety results and US FDA Pediatric Rare Disease Designation.

Discover more about therapies set to grab major Netherton Syndrome market share @ Netherton Syndrome Treatment Landscape

Recent Development in the Netherton Syndrome Treatment Landscape

• In November 2025, BioCryst Pharmaceuticals reported that initial data from Netherton Syndrome patients enrolled in the Phase I clinical trial of BCX17725 are expected by the end of Q1 2026, with plans for a pivotal study in 2027.

• In October 2025, the US FDA granted Orphan Drug Designation to Quoin Pharmaceuticals’ QRX003 for Netherton Syndrome, following EMA designation in May 2025.

• In June 2025, QRX003 also received Rare Pediatric Disease Designation from the US FDA.

• In July 2025, the US FDA granted Fast Track Designation to BCX17725 for the treatment of Netherton Syndrome.

• In August 2025, Azitra announced that topline data from the Phase Ib trial of ATR-12 are expected in Q1 2026.

What is Netherton Syndrome?

Netherton Syndrome, also referred to as Comel-Netherton Syndrome, is a rare and serious inherited disorder passed down in an autosomal recessive pattern. It is characterized by widespread red, scaly skin resembling ichthyosis, a distinctive hair shaft defect known as trichorrhexis invaginata or “bamboo hair,” and a strong tendency toward allergic conditions.

The disease arises from mutations in the SPINK5 gene, leading to deficiency of the LEKTI protein. Current treatment options are limited and mainly focus on symptom management rather than targeting the root cause.

Netherton Syndrome Epidemiology Segmentation

The Netherton Syndrome market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Netherton Syndrome

• Gender-specific Cases of Netherton Syndrome

• Diagnosed Prevalent Cases of Netherton Syndrome in the US

• Diagnosed Prevalent Cases in EU4 and the UK

• Diagnosed Prevalent Cases in Japan

Download the report to understand which factors are driving Netherton Syndrome epidemiology trends @ Netherton Syndrome Epidemiology Forecast

Scope of the Netherton Syndrome Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Companies: Quoin Pharmaceuticals, BioCryst Pharmaceuticals, Azitra, and others

• Key Therapies: QRX003, BCX17725, ATR-12, and others

• Market Dynamics: Drivers and Barriers

• Competitive Intelligence Analysis: SWOT, market entry strategies, reimbursement scenario

• Unmet Needs, KOL Views, Analyst Views, Market Access and Reimbursement

To know more about Netherton Syndrome companies working in the treatment market, visit @ Netherton Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents

1. Netherton Syndrome Market Report Introduction

2. Executive Summary for Netherton Syndrome

3. SWOT Analysis of Netherton Syndrome

4. Netherton Syndrome Patient Share (%) Overview at a Glance

5. Netherton Syndrome Market Overview at a Glance

6. Netherton Syndrome Background and Overview

7. Netherton Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Netherton Syndrome

9. Netherton Syndrome Current Treatment and Medical Practices

10. Netherton Syndrome Unmet Needs

11. Netherton Syndrome Emerging Therapies

12. Netherton Syndrome Market Outlook

13. Country-Wise Netherton Syndrome Market Analysis (2022–2036)

14. Netherton Syndrome Market Access and Reimbursement of Therapies

15. Netherton Syndrome Market Drivers

16. Netherton Syndrome Market Barriers

17. Netherton Syndrome Appendix

18. Netherton Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services